How closely should a nonprofit resemble a corporation? And what happens when a nonprofit operates more like a corporation than a nonprofit? The Broad Institute of MIT and Harvard faces these questions after winning the ability to legally license their gene-editing technology, CRISPR-Cas9, earlier this year. As the Broad sells IP licenses for their CRISPR technology, many fear that lack of regulation could lead to some controversy with taxpayers. Think: using technology built on public funding to genetically modify crops.
As nonprofits start to resemble corporations, companies continue to resemble nonprofits. The Public Benefit Corporation, Perlara PBC, is among a new class of corporations that are legislatively recognized for providing social and environmental benefit.
Noteworthy Outcomes: Can This Wonder Drug Fight Neurodegenerative Diseases?
A new development from the neurology world has scientists hopeful about a drug with the potential to slow neurodegenerative diseases, such as dementia.
However, there’s still a lot of research left to be done to back up the “wonder drug” claims.
“Right now it’s only a wonder drug in brain cell lines and rodents,” points out Joel Dudley, Director of the Institute for Next Generation Healthcare at Mount Sinai. “But we do hope for positive results in humans, and I believe that repurposing existing drugs will be a fruitful path to discover new therapies for Alzheimer’s diseases.”
Encounters with Data: Running for Longevity
If your weekend plans involve lacing up a pair of running sneakers and hitting the pavement, new research suggests that you’re likely to live longer, just for keeping up your running habit. You’re also less likely to have a premature death, suffer from cardiovascular disease, some cancers, depression, and diabetes. And, you may even qualify for lower life insurance rates, as insurers like Health I.Q. find ways to incorporate health data, such as how fast you can run a mile, into their pricing models.